Ambroxol in the treatment of acute bronchitis and COVID-19
- Авторлар: Alieva A.M.1, Batov M.A.2, Karabinenko A.A.1
-
Мекемелер:
- N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
- P.A. Herzen Moscow Scientific And Research Oncological Institute of Oncology - a branch of National Medical Research Radiological Centre of the Ministry of Healthcare of Russia
- Шығарылым: Том 8, № 6 (2022)
- Беттер: 151-156
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/289161
- DOI: https://doi.org/10.18565/therapy.2022.6.151-156
- ID: 289161
Дәйексөз келтіру
Аннотация
Acute bronchitis (AB) is one of the most common conditions encountered in outpatient clinical practice. Before the COVID-19 pandemic, the U.S. Centers for Disease Control estimated that acute bronchitis accounted for about 10% of GP visits, or about 100 million visits per year. Ambroxol has mucokinetic and mucociliary effects that have been shown in clinical studies involving adult patients with respiratory disease, and therefore has potential for use in both OB and COVID-19. The aim of this review is to analyze clinical data on the use of ambroxol in actual medical practice in patients with AB. Comparatively convincing data on the effectiveness of ambroxol as a component of symptomatic and pathogenetic therapy of AB are presented. Studies on the efficacy of ambroxol administration in patients with COVID-19 have great prospects for introduction into clinical practice and are under active study.
Негізгі сөздер
Толық мәтін
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Авторлар туралы
Amina Alieva
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia
Email: amisha_alieva@mail.ru
PhD in Medicine, associate professor of the Department of hospital therapy No. 2 of the Faculty of general medicine
Maxim Batov
P.A. Herzen Moscow Scientific And Research Oncological Institute of Oncology - a branch of National Medical Research Radiological Centre of the Ministry of Healthcare of Russiaresident doctor
Alexander Karabinenko
N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of RussiaDr. med. habil., professor of the Department of hospital therapy No. 2 of the Faculty of general medicine
Әдебиет тізімі
- Zhou P., Yang X.L., Wang X.G. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-73. https://dx.doi.org/10.1038/s41586-020-2012-7.
- Yelin D., Wirtheim E., Vetter P. et al. Long-term consequences of COVID-19: Research needs. Lancet Infect Dis. 2020; 20(10): 1115 -17. https://dx.doi.org/10.1016/S1473-3099(20)30701-5.
- Blackwell D.L., Lucas J.W., Clarke T.C. Summary health statistics for U.S. adults: national health interview survey, 2012. Vital Health Stat 10. 2014; 260: 1-161.
- Леонов С.А., Сон И.М., Моравская С.В. Динамика заболеваемости с временной утратой трудоспособности в Российской Федерации в 2007-2011 годах. Менеджер здравоохранения. 2013; 8: 6-14. [Leonov S.A., Son I.M., Moravskaya S.V. Dynamics of morbidity with a temporary disabilityin Russian Federationin the period of 200 -2011 years. Menedzher zdravookhraneniya = Healthcare Manager: 2013; K: 6-P4 (in Russ.)]. EDN: RBTBKB.
- Лебедева-Несевря Н.А., Костарев В.Г., Никифорова Н.В., Цинкер М.Ю. Заболеваемость с временной утратой трудоспособности работающего населения: федеральные и региональные показатели и тенденции 2005-2014 гг. Гигиена и санитария. 2017; 96(11): 1054-1059. [Lebedeva-Nesevrya N.A., Kostarev V.G., Nikiforova N.V., Tsinker M.Yu. Morbidity with temporary loss of work capacity in working population: federal and regional indices and trends over 200K-2014. Gigiena i sanitariya = Hygiene and Sanitation Russian Journal. 2017; 96(11): 1054-1059 (In Russ.)]. https://dx.doi.org/10.18821/0016-9900-2017-96-11-1054-1059. EDN: YOBWVJ.
- Harris A.M., Hicks L.A., Qaseem A.; High value care task force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: Advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2016; 164(6): 425-34. https://dx.doi.org/10.7326/M15-1840.
- Wenzel R.P., Fowler A.A. 3rd. Clinical practice. Acute bronchitis. N. Engl J. Med. 2006; 355(20): 2125-30. https://dx.doi.org/10.1056/NEJMcp061493.
- Jonsson J.S., Sigurdsson J.A., Kristinsson K.G. et al. Acute bronchitis in adults. How close do we come to its aetiology in general practice? Scand J. Prim Health Care. 1997; 15(3): 156-60. https://dx.doi.org/10.3109/02813439709018507.
- Creer D.D., Dilworth J.P., Gillespie S.H. et al. Aetiological role of viral and bacterial infections in acute adult lower respiratory tract infection (LRTI) in primary care. Thorax. 2006; 61(1): 75-79. https://dx.doi.org/10.1136/thx.2004.027441.
- Bai L., Su X., Zhao D. et al. Exposure to traffic-related air pollution and acute bronchitis in children: Season and age as modifiers. J. Epidemiol Community Health. 2018; 72(5): 426-33. https://dx.doi.org/10.1136/jech-2017-209948.
- Saust L.T., Bjerrum L., Siersma V. et al. Quality assessment in gendnal practice: diagnosis and aeti°iotin treatment of acute respiratory tract infections. Scand J. Prim Health Care. 2018; 36(4): 372-79. https://dx.doi.org/10_108(Do02813432.2018.1523996.
- Kinkade S., Long N.A. Acute bronchitis. Am Fam Physician. 2016; 94(7): 560-65.
- Jonsson J.S., Gislason T., Gislason D., Sigurdsson J.A. Acute bronchitis and clinical outcome three years later: Prospective cohort study. BMJ. 1998; 317(7170): 1433. https://dx.doi.org/10.1136/bmj.317.7170.1433.
- Braman S.S. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006; 129(1 Suppl): 95S-103S. https://dx.doi.org/10.1378/chest.129.1_suppl.95S.
- Ebell M.H., Lundgren J., Youngpairoj S. How long does a cough last? Comparing patients' expectations with data from a systematic review of the literature. Ann Fam Med. 2013; 11(1): 5-13. https://dx.doi.org/10.1370/afm.1430.
- Schroeder K., Fahey T. Should we advise parents to administer over the counter cough medicines for acute cough? Systematic review of randomised controlled trials. Arch Dis Child 2002; 86(3): 170-75. https://dx.doi.org/10.1136/adc.86.3.170.
- European Medicine Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal product. 10 September 2015. URL: https://www.ema.europa.eu/en/documents/referral/ambroxol-bromhexine-article-31-referral-prac-assessment-report_ en.pdf (date of access - 01.08.2022).
- Cazan D., Klimek L., Sperl A. et al. Safety of ambroxol in the treatment of airway diseases in adult patients. Expert Opin Drug Saf. 2018; 17(12): 1211-24. https://dx.doi.org/10.1080/14740338.2018.1533954.
- Zanasi A., Mazzolini M., Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidisci Respir Med. 2017; 12: 7. https://dx.doi.org/10.1186/s40248-017-0088-1.
- Yang B., Yao D.F., Ohuchi M. et al. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels. Eur Respir J. 2002; 19(5): 952-58. https://dx.doi.org/10.1183/09031936.02.00253302.
- Gupta P.R. Ambroxol - resurgence of an old molecule as an anti-inflammatory agent in chronic obstructive airway diseases. Lung India. 2010; 27(2): 46-48. https://dx.doi.org/10.4103/0970-2113.63603.
- Muroi Y., Undem B.J. Targeting voltage gated sodium channels NaV1.7, Na V1.8, and Na V1.9 for treatment of pathological cough. Lung. 2014; 192(1): 15-20. https://dx.doi.org/10.1007/s00408-013-9533-x.
- Li F., Yu J., Yang H. et al. Effects of ambroxol on alginate of mature Pseudomonas aeruginosa biofilms. Curr Microbiol. 2008; 57(1): 1-7. https://dx.doi.org/10.1007/s00284-008-9142-8.
- Deretic V., Timmins G.S. Enhancement of lung levels of antibiotics by ambroxol and bromhexine. Expert Opin Drug Metab Toxicol.2019; 15(3): 213-18. https://dx.doi.org/10.1080/17425255.2019.1578748.
- Matthys H., de Mey C., Carls C. et al. Efficacy and tolerability of myrtol standardized in acute bronchitis. A multi-centre, randomised, double-blind, placebo-controlled parallel group clinical trial vs. cefuroxime and ambroxol. Arzneimittelforschung. 2000; 50(8): 700-11. https://dx.doi.org/10.1055/s-0031-1300276.
- Schulz M., Hammerlein A., Hinkel U. et al. Safety and usage pattern of an over-the-counter ambroxol cough syrup: A community pharmacy-based cohort study. Int J. Clin Pharmacol Ther. 2006; 44(9): 409-21. https://dx.doi.org/10.5414/cpp44409.
- Kardos P., Beeh K.M., Sent U. et al. Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations. BMC Pharmacol Toxicol. 2018; 19(1): 40. https://dx.doi.org/10.1186/s40360-018-0229-y.
- Kumar P. Co-aerosolized pulmonary surfactant and ambroxol for COVID-19 ARDS Intervention: What are we waiting for? Front Bioeng Biotechnol. 2020; 8: 577172. https://dx.doi.org/10.3389/fbioe.2020.577172.
- Bocci G., Bradfute S.B., Ye C. et al. Virtual and in vitro antiviral screening revive therapeutic drugs for COVID-19. ACS Pharmacol Transl Sci. 2020; 3(6): 1278-92. https://dx.doi.org/10.1021/acsptsci.0c00131.
- Bradfute S.B., Ye C., Clarke E.C. et al. Ambroxol and ciprofloxacin show activity against SARS-CoV2 in Vero E6 cells at clinically-relevant concentrations. bioRxiv. 2020; 2020.08.11.245100. https://dx.doi.org/10.1101/2020.08.11.245100. Preprint.
- Olaleye O.A., Kaur M., Onyenaka C.C. Ambroxol hydrochloride inhibits the interaction between severe acute respiratory syndrome coronavirus 2 spike protein's receptor binding domain and recombinant human ACE2. bioRxiv. 2020; 2020.09.13.295691. https://dx.doi.org/10.1101/2020.09.13.295691. Preprint.
- Carpinteiro A., Gripp B., Hoffmann M. et al. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells. J. Biol Chem. 2021; 296: 100701. https://dx.doi.org/10.1016/j.jbc.2021.100701.
Қосымша файлдар
![](/img/style/loading.gif)